OMER: Omeros Corp.
About
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Current Value
$6.001 Year Return
Current Value
$6.001 Year Return
Key Details
Market Cap
$349.44M
P/E Ratio
-2.62
1Y Stock Return
258.93%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
-2.3
Strategies that include OMER
Stock's related to OMER
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HOOD | 41.68% | $31.15B | +341.60% | 0.00% |
| UPWK | 38.43% | $2.00B | +9.38% | 0.00% |
| CLFD | 38.36% | $398.66M | +4.48% | 0.00% |
| KTOS | 38.31% | $3.78B | +33.46% | 0.00% |
| COIN | 38.16% | $81.26B | +207.68% | 0.00% |
| ALT | 37.52% | $531.30M | +194.09% | 0.00% |
| S | 36.21% | $8.76B | +59.38% | 0.00% |
| VSTO | 36.14% | $2.58B | +71.61% | 0.00% |
| VRDN | 35.76% | $1.60B | +28.92% | 0.00% |
| OCUL | 35.67% | $1.40B | +307.31% | 0.00% |
| PTGX | 35.35% | $2.30B | +122.64% | 0.00% |
| RIOT | 35.08% | $4.08B | +9.85% | 0.00% |
| RXST | 35.02% | $1.82B | +62.89% | 0.00% |
| RVMD | 35.02% | $9.50B | +171.62% | 0.00% |
| SANA | 33.76% | $526.91M | -41.15% | 0.00% |
| YALA | 33.14% | $587.51M | -23.43% | 0.00% |
| ALNT | 33.10% | $419.62M | -4.92% | 0.36% |
| ANGI | 32.32% | $987.36M | -5.71% | 0.00% |
| GSM | 32.08% | $843.60M | -8.18% | 0.86% |
| IFRX | 31.97% | $113.06M | +31.51% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BCAN | -0.01% | $72.87M | -99.75% | 0.00% |
| DSP | -0.06% | $292.39M | +215.22% | 0.00% |
| OII | 0.07% | $2.78B | +32.07% | 0.00% |
| SHEL | -0.08% | $205.19B | -1.07% | 4.20% |
| CANG | 0.09% | $253.50M | +212.50% | 0.00% |
| GPRK | -0.09% | $440.00M | -9.95% | 6.37% |
| CRON | -0.12% | $776.06M | 0.00% | 0.00% |
| DLTH | 0.14% | $124.02M | -31.26% | 0.00% |
| CAG | 0.17% | $12.64B | -6.10% | 5.26% |
| PTMN | -0.21% | - | - | 16.06% |
| DXYZ | -0.21% | - | - | 0.00% |
| HLX | 0.22% | $1.60B | +13.04% | 0.00% |
| ARLP | -0.23% | $3.54B | +26.77% | 10.11% |
| SUZ | -0.23% | $13.00B | -2.96% | 2.27% |
| CNQ | -0.26% | $71.04B | +1.89% | 6.81% |
| KVUE | 0.30% | $45.42B | +19.05% | 3.43% |
| UPLD | 0.30% | $87.26M | -26.39% | 0.00% |
| WRB | 0.31% | $22.94B | +29.98% | 0.69% |
| MUR | 0.36% | $4.74B | -23.99% | 3.70% |
| VZIO | 0.37% | $2.29B | +67.76% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LDOS | -25.71% | $21.12B | +49.80% | 0.96% |
| CNSL | -21.68% | $548.51M | +9.98% | 0.00% |
| TTEK | -20.29% | $10.90B | +23.97% | 2.70% |
| KBR | -19.51% | $7.77B | +11.73% | 1.00% |
| SAIC | -18.45% | $5.92B | +3.71% | 1.24% |
| LMT | -17.23% | $126.40B | +18.99% | 2.36% |
| GD | -16.95% | $77.26B | +14.02% | 1.98% |
| TPST | -15.76% | $37.75M | -77.59% | 0.00% |
| NOC | -15.06% | $71.54B | +4.23% | 1.60% |
| HSY | -14.43% | $34.45B | -10.68% | 3.21% |
| OPRX | -13.60% | $75.16M | -58.02% | 0.00% |
| BAH | -13.38% | $17.62B | +9.13% | 1.47% |
| VZ | -12.89% | $176.51B | +12.56% | 6.37% |
| CAH | -12.86% | $28.64B | +12.14% | 1.70% |
| GIS | -11.91% | $34.85B | -2.91% | 3.78% |
| SPH | -11.39% | $1.15B | +6.07% | 7.25% |
| XOS | -11.33% | $30.51M | -57.24% | 0.00% |
| MNR | -11.26% | $1.66B | -10.71% | 15.90% |
| CACI | -11.14% | $9.96B | +37.84% | 0.00% |
| AON | -11.00% | $82.00B | +16.33% | 0.70% |
ETF's related to OMER
News
SeekingAlpha
OMIDRIA, Omeros' one approved therapy, has provided boosts to its fraught liquidity over the years. Read why OMER stock is a Hold.
Yahoo
Q3 2024 Omeros Corp Earnings Call
Yahoo
Omeros Corp (OMER) reports reduced net loss and strategic progress in clinical programs, despite financial challenges and market competition.
SeekingAlpha
Omeros Corporation (NASDAQ:OMER) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsJennifer Cook Williams - Investor and...
Yahoo
SEATTLE (AP) — Omeros Corporation OMER on Wednesday reported a loss of $32.2 million in its third quarter. On a per-share basis, the Seattle-based company said it had a loss of 56 cents. Losses, adjusted to account for discontinued operations, came to 64 cents per share.
Yahoo
SEATTLE, November 13, 2024--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include:
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.